Abciximab vs. Eptifibatide for Primary Percutaneous Coronary Intervention

An analysis of registry data reveals heavier use of eptifibatide than abciximab and similar short-term outcomes with both agents.

Many physicians choose eptifibatide when selecting a glycoprotein IIb/IIIa inhibitor for primary percutaneous coronary intervention, even though more randomized trial data are available to support abciximab in this setting. In this observational study, investigators used a large Michigan registry to compare the outcomes achieved with these two agents in 3541 patients undergoing primary PCI for ST-segment-elevation MI.

The 729 abciximab recipients were more likely to be on dialysis and have angiographically evident thrombus, and less likely to receive preprocedural clopidogrel, than were the 2812 eptifibatide recipients. After multivariate and propensity adjustments, there were no significant between-group differences in in-hospital rates of …

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)